

Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis

Jochen T. Frueh, Julia Campe, Daniele Yumi Sunaga-Franze, Nikita A. Verheyden, Sakhila Ghimire, Elisabeth Meedt, Denise Haslinger, Sabine Harenkamp, Daniel Staudenraus, Sascha Sauer, Andreas Kreft, Ralf Schubert, Michael Lohoff, Andreas Krueger, Halvard Bonig, Andreas G. Chiocchetti, Robert Zeiser, Ernst Holler & Evelyn Ullrich

To cite this article: Jochen T. Frueh, Julia Campe, Daniele Yumi Sunaga-Franze, Nikita A. Verheyden, Sakhila Ghimire, Elisabeth Meedt, Denise Haslinger, Sabine Harenkamp, Daniel Staudenraus, Sascha Sauer, Andreas Kreft, Ralf Schubert, Michael Lohoff, Andreas Krueger, Halvard Bonig, Andreas G. Chiocchetti, Robert Zeiser, Ernst Holler & Evelyn Ullrich (2024) Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis, *Oncoimmunology*, 13:1, 2296712, DOI: [10.1080/2162402X.2023.2296712](https://doi.org/10.1080/2162402X.2023.2296712)

To link to this article: <https://doi.org/10.1080/2162402X.2023.2296712>



© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.



[View supplementary material](#)



Published online: 27 Dec 2023.



[Submit your article to this journal](#)



Article views: 337




[View related articles](#)



[View Crossmark data](#)

Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis

Jochen T. Frueh^{a,b*}, Julia Campe^{a,b*}, Daniele Yumi Sunaga-Franze^c, Nikita A. Verheyden^{d,e}, Sakhila Ghimire^f, Elisabeth Meedt^f, Denise Haslinger^g, Sabine Harenkamp^h, Daniel Staudenrausⁱ, Sascha Sauer^c, Andreas Kreft^j, Ralf Schubert^k, Michael Lohoffⁱ, Andreas Krueger^{d,e,l}, Halvard Bonig^{h,m}, Andreas G. Chiocchetti^g, Robert Zeiserⁿ, Ernst Holler^f, and Evelyn Ullrich^{o,p} 

^aDepartment of Pediatrics, Experimental Immunology and Cell Therapy, Goethe University Frankfurt, Frankfurt am Main, Germany; ^bDepartment of Pediatrics, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; ^cGenomics Platform, Max Delbrueck Center for Molecular Medicine, Berlin Institute of Health, Berlin, Germany; ^dInstitute for Molecular Medicine, University Hospital, Goethe University Frankfurt, Frankfurt, Germany; ^eMolecular Immunology, Justus Liebig University Giessen, Giessen, Germany; ^fHematology and Oncology Department, Medical Clinic 3, University Hospital Regensburg, Regensburg, Germany; ^gDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; ^hGerman Red Cross Blood Service BaWüHe, Frankfurt am Main, Germany; ⁱInstitute for Microbiology, Philipps University, Marburg, Germany; ^jInstitute of Pathology, University Medical Center Mainz, Mainz, Germany; ^kDepartment of Pediatric Medicine, Division of Pneumology, Allergology, Infectious diseases und Gastroenterology, Frankfurt am Main, Goethe University Frankfurt, Frankfurt, Germany; ^lFrankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; ^mInstitute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany; ⁿDepartment of Internal Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; ^oGerman Cancer Consortium (DKTK), partner site Frankfurt/Mainz, a partnership between DKFZ, University Hospital Frankfurt, Frankfurt, Germany; ^pUniversity Cancer Center (UCT), Frankfurt am Main, Germany

ABSTRACT

Interferon regulatory factor 4 (IRF4) is a master transcription factor that regulates T helper cell (Th) differentiation. It interacts with the Basic leucine zipper transcription factor, ATF-like (BATF), depletion of which in CD4⁺ T cells abrogates acute graft-versus-host disease (aGVHD)-induced colitis. Here, we investigated the immune-regulatory role of *Irf4* in a mouse model of MHC-mismatched bone marrow transplantation. We found that recipients of allogenic *Irf4*^{-/-} CD4⁺ T cells developed less GVHD-related symptoms. Transcriptome analysis of re-isolated donor *Irf4*^{-/-} CD4⁺ T helper (Th) cells, revealed gene expression profiles consistent with loss of effector T helper cell signatures and enrichment of a regulatory T cell (Treg) gene expression signature. In line with these findings, we observed a high expression of the transcription factor BTB and CNC homolog 2; (BACH2) in *Irf4*^{-/-} T cells, which is associated with the formation of Treg cells and suppression of Th subset differentiation. We also found an association between BACH2 expression and Treg differentiation in patients with intestinal GVHD. Finally, our results indicate that IRF4 and BACH2 act as counterparts in Th cell polarization and immune homeostasis during GVHD. In conclusion, targeting the BACH2/IRF4-axis could help to develop novel therapeutic approaches against GVHD.

ARTICLE HISTORY

Received 30 May 2023
Revised 12 December 2023
Accepted 14 December 2023

KEYWORDS

Acute GVHD; BACH2; IRF4;
T helper cells


Introduction

Graft-versus-host disease (GVHD) is a frequent complication after hematopoietic stem cell transplantation (HSCT) and still associated with high morbidity and mortality.^{1–5} Acute GVHD (aGVHD) emerges due to differences in minor and major histocompatibility antigens (HLA) between donor and recipients leading to activation of allogenic T cells and induction of the disease.⁶


To date, the role of the distinct T helper cell (Th)-subsets in GVHD pathogenesis is not completely understood. Th-1 cells and regulatory T cells (Treg) induce and suppress GVHD, respectively.^{7–15} Whereas numerous publications have shown that Th-2 cells are more suppressive,^{11,15–18} the Th-17 cells are thought to be responsible for the development of severe aGVHD.^{7,15,19–21}

Interestingly, these subsets share the transcription factor Interferon Regulatory Factor 4 (IRF4) which regulates T cell fate decisions.²² IRF4 is not only essential for the formation of Th-2, Th-9, Th-17 and T-follicular helper cells (Tfh), but also acts as a central regulator for Th-1 cells.^{23–33} Additionally, IRF4 plays an important role in Th-driven autoimmune diseases, transplant rejection and inflammatory bowel disease.^{34–36} Furthermore, IRF4 was found to regulate the differentiation of different Treg subsets.^{36–38}

Here, we investigated the immune regulatory role of IRF4 in aGVHD. In an allogenic bone marrow transplantation (BMT) mouse model, recipients of *Irf4*^{-/-} CD4⁺ T cells developed reduced clinical GVHD symptoms and GVHD-associated colitis compared to controls. We found lower expression of effector T helper cell signature genes while

CONTACT Evelyn Ullrich  evelyn@ullrichlab.de  Department of Pediatrics, Experimental Immunology and Cell Therapy, Goethe University Frankfurt, Frankfurt am Main, Germany

*authors contributed equally.

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/2162402X.2023.2296712>.

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

transcripts associated with Treg cell development, including the transcription factor BTB and CNC homolog 2 (*BACH2*) were more abundant in the absence of *Irf4*. Remarkably, we observed a similar impact of *BACH2* on Treg differentiation and of *IRF4* on inflammatory processes in patients with intestinal GVHD.

In summary, our results indicate that *IRF4* and *BACH2* act as counterparts in Th cell subset polarization and immune homeostasis in the development of GVHD.

Material and methods

Study approval

All mouse experiments were approved by the government committee (Regierungspräsidium Darmstadt, Germany) and conducted in accordance with the requirements of the German Animal Welfare Act. The patient biopsy studies and scientific analysis were approved by the local ethical review board (approval no 02/220 and 09/059) and were performed in accordance with the Declaration of Helsinki. All patients consented for biopsy.

Bone marrow transplantation and GVHD mouse model

A full MHC-mismatch C57BL/6 → BALB/c model was used for aGVHD studies *in vivo*. Briefly, BALB/c recipient mice were lethally irradiated with 8 Gy at day 0. Bone marrow cells were isolated from C57BL/6 donors, depleted for CD90.2 positive T-cells (MACS mouse CD90.2 microbeads, Miltenyi) and transplanted with a dose of 5×10^6 bone marrow cells per recipient at day 1. CD4⁺ T cells were isolated from spleens of F2- and F3-generation C57BL/6-*IRF4*^{-/-}-CD45.1-Luc⁺ (*Irf4*^{-/-}) or C57BL/6-*IRF4*^{+/-}-CD45.1-Luc⁺ (*Irf4*^{+/-}) mice or wild type C57BL/6-CD45.1-Luc⁺ (WT) mice via MACS mouse CD4⁺ T cell negative selection (Miltenyi) at day 2 and transplanted with a dose of 1×10^6 cells per BALB/c recipient. Control BALB/c mice did not receive CD4⁺ T cells (bone marrow transplantation (BMT) control). GVHD development was tracked over 14–30 days by regular control of the GVHD score.³⁹ Mice from the WT and *Irf4*^{+/-} group were euthanized latest 14–16 days after irradiation, whereas a fraction of mice from the *Irf4*^{-/-} and BMT control group was analyzed for a longer period. Of note, mice did not receive any GvHD prophylaxis or treatment during the entire observation time.

In vivo bioluminescence imaging (BLI)

Luciferase positive CD4⁺ T cells derived from T cell donors were tracked *in vivo* using the IVIS Lumina II device (PerkinElmer). 100 μL luciferin (15 mg/mL, Promega) were injected subcutaneously 15 minutes before measurement start. Bioluminescence was measured and analyzed with Living Image Software (PerkinElmer). *In vivo* tracking of the cells was performed until day 13 with an interval of 2–3 days. Target organ specific migration of the Luc⁺ cells was measured at day 14 or 15 in the respective isolated organs.

Flow cytometry and cell sorting

For T cell phenotyping, cells were stained with the following antibodies: anti-CD122 (TM-beta1), anti-CD127 (A7R34), anti-CD25 (PC61), anti-CD3 (17A2), anti-CD4 (GK1.5), anti-CD44 (REA664 or IM7), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD62L (MEL-14), anti-CD69 (H1-2F3), anti-CD8 (53–6.7). Intracellular staining was performed with the transcription factor buffer set (BD Pharmingen) and the following antibodies: anti-Foxp3 (REA788), anti-Helios (22F6), anti-IFN-γ (XMG1.2), anti-IL-17A (TC11-18H10.1), anti-IL-4 (11B11). For live/dead discrimination cells were stained with 7AAD (BD Pharmingen) or LIVE/DEAD Fixable Near-IR stain (Invitrogen).

For sorting of CD45.1⁺ CD4⁺ cells the following staining antibodies were used: anti-Nkp46 (29A1.4), anti-CD8 (53–6.7), anti-CD19 (6D5), anti-CD3 (145-2C11), anti-CD45.1 (A20), antiCD4 (GK1.5), 7AAD staining (BD). All antibodies were purchased from BD, Biolegend, eBioscience or Miltenyi.

Isolation of RNA, cDNA synthesis and RNA sequencing analysis

For RNA sequencing CD4⁺ T cells were re-isolated from recipient mouse spleens using the CD4⁺ T cell isolation Kit II (Miltenyi) and then sorted for CD45.1 with >99% purity. RNA was isolated using the RNeasy Mini or Micro Kit (Qiagen) depending on the cell number. RNA libraries for sequencing were prepared with Paired-End TruSeq Cluster Kit and sequenced on an Illumina HiSeq 4000 instrument (2×76 bp) with an average read depth of 23 million reads. Adapter sequences were trimmed (Trimmomatic v0.36)⁴⁰ and low-quality reads were filtered out. Reads were mapped to Ensembl Gencode GRCm38 using STAR v2.5.3a.⁴¹ RSEM v1.3.0⁴² was used to quantify the expression of transcripts. DESeq2 R package v1.16.1⁴³ was used with default parameters to find the differentially expressed genes. The sequencing data generated in this study have been deposited in the EMBL BioStudies under accession number [S-BSST1167].

Patient characteristics

109 intestinal biopsies were obtained and analyzed from 76 adult patients receiving allogeneic stem cell transplantation between January 2012 and March 2016. Patient characteristics are summarized in Supplemental Table S1.

Statistical analyses

Statistical analyzes were performed with the Graphpad Prism software (version 9). Non-parametric tests were applied as indicated in the respective figure legends. A p-value <0.05 was considered as statistically significant.

Results

Irf4^{-/-} CD4⁺ T cell do not induce acute GVHD in an allogeneic mouse model

To determine whether *Irf4* expression in CD4⁺ T cells impacts intestinal acute GVHD development, we

transplanted *Irf4*-sufficient (*Irf4*^{+/+} and wild type (WT)) or *Irf4*-deficient (*Irf4*^{-/-}) CD4⁺ T cells from C57BL/6 mice to a C57/Bl6 (H2^b) → BALB/c (H2^d) model (Figure 1a). Recipients transplanted with either WT or *Irf4*^{+/+} T cells developed GVHD to a similar degree and in a cell-dose dependent manner, suggesting that heterozygous loss of *Irf4* is not associated with a gene-dosage effect in this model system (Figure 1b, Supplemental Figure S1A). In contrast, *Irf4*^{-/-} CD4⁺ T cells failed to induce GVHD above scores also observed in BMT control mice irrespective of CD4⁺ T cell numbers transplanted. GVHD-associated colitis was advanced in recipients of WT CD4⁺ T cells on day 14 after total body irradiation (TBI), whereas the colon of recipients of *Irf4*^{-/-} CD4⁺ T cells appeared healthy also on day 30

(Figure 1c, Supplemental Figure S1B). This finding was confirmed by histopathology scoring of colon sections (Figure 1d, Supplemental Figure S1C).

Serum concentrations of IL-6, IL-2 and TNF and of the anti-inflammatory cytokine IL-10, but not IFN- γ , were elevated on day 15 post TBI in recipients of *Irf4*[±] and WT CD4⁺ T cells (Supplemental Figure S1D). In contrast, recipients of *Irf4*^{-/-} CD4⁺ T cells showed similar serum cytokine concentrations as the BMT control group, indicating the absence of inflammatory processes.

Overall, these data indicate that *Irf4* expression in CD4⁺ T cells contributes to aGVHD-associated colitis, and systemic inflammation in our murine full MHC-mismatch model of aGVHD.




Figure 1. *Irf4*^{-/-} CD4⁺ T cell induce less aGVHD and GVHD associated colitis. Lethally irradiated BALB/c recipients that received 5×10^6 CD45.2⁺ WT BL/6 BM depleted for CD90.2⁺ cells at day one and 1×10^6 CD4⁺ CD45.1⁺ Luciferase⁺ T cells from WT, *Irf4*^{-/-} or *Irf4*[±] donors with BL/6 background at day two (a) were monitored every 2–3 days for clinical GVHD score (b) and for colitis development at the end of the experiment (c). Data represent the mean \pm standard deviation combined from 3 to 8 independent experiments (a–b: BM = 8, *Irf4*^{-/-} = 7, *Irf4*[±] = 4, WT = 5 experiments; c: all groups = 3 experiments). (d) The colons of BM and CD4⁺ T cell recipients were analyzed at day 14 post irradiation. Histological sections were stained with Hematoxylin/Eosin (HE) and scored for histopathological changes. One representative picture is shown per condition. Data represent the mean \pm standard deviation combined from 1 to 3 independent experiments (BM = 2, *Irf4*^{-/-} = 2, *Irf4*[±] = 1, WT = 3 experiments). If applicable, all data points each representing an individual are shown. ***P* < .01, ****P* < .005, *****P* < .0001. Analyses were performed with the two tailed Mann-Whitney test.

Irf4^{-/-} CD4⁺ T cells migrate to GVHD target organs with impaired proliferation capacity

Next, we assessed whether the difference in aGVHD development between recipients of *Irf4*^{-/-}, *Irf4*^{+/-} and WT CD4⁺ T cells can be explained by alterations in migration to GVHD target organs or defective T cell expansion, as we had also observed *in vitro* (Supplemental Figure S2A). We observed lower frequencies of donor CD45.1⁺ CD4⁺ T cells in spleens from the *Irf4*^{-/-} group in comparison to WT and *Irf4*^{+/-} group (Figure 2a). Moreover, we traced the spatial and temporal distribution of the transplanted Luciferase-positive (Luc⁺) CD4⁺ T cells by bioluminescence signal. Bioluminescence intensity revealed substantially reduced expansion of donor *Irf4*^{-/-} CD4⁺ T cells in

comparison to the WT group (Figure 2b,c). Bioluminescence imaging (BLI) also showed lower amounts of Luc⁺ CD4⁺ T cells in the GVHD target organs lung, liver, and colon, on day 15 (Figure 2d,e, Supplemental Figure S2B and C). However, we did not detect qualitative differences in tissue distribution dependent on donor genotype, suggesting that loss of *Irf4* does not affect homing of T cells to GVHD target organs. Furthermore, we noticed that transplanted *Irf4*^{-/-} CD4⁺ T cell showed delayed expansion to the same GVHD target organs as WT and *Irf4*^{+/-} CD4⁺ T cells without eliciting disease at these later time points. (Figure 2b; Figure 1b; Supplemental Figure S1B and C; Supplemental Figure S2b – e). This finding implies that impaired expansion of *Irf4*^{-/-} CD4⁺ T cells early after transplantation




Figure 2. *Irf4*^{-/-} CD4⁺ T cells show decelerated proliferation but migrate to the same aGVHD target organs like WT and *Irf4*^{+/-} CD4⁺ T cells. The migration of 1×10^6 CD4⁺ CD45.1⁺ Luciferase⁺ T cells from WT (red), *Irf4*^{-/-} (blue) or *Irf4*^{+/-} (orange) donors with BL/6 background in the lethally irradiated WT BL/6 CD0.2-depleted BM transplanted recipients was traced by measuring the frequency of CD45.1⁺ CD4⁺ T cells in the spleen at day 15 after irradiation via flow cytometry (a) and by bioluminescent imaging of the Luc⁺ CD4⁺ T cells considering the total bioluminescence signal (b) and the signal distribution throughout the body (c) at different time points. At day 14/15 (d, e) and day 31 (d, e) bioluminescent signal was additionally measured in the spleen and colon after dissection. Representative BLI pictures for the respective groups are shown. Data represent the mean \pm standard deviation combined from independent experiments. If applicable, all data points each representing an individual are shown. * $P < .05$, ** $P < .01$, *** $P < .005$, **** $P < .0001$. The legend of Figure 2 applies for all subfigures. Analyses were performed with the two tailed Mann-Whitney test.

cannot fully explain attenuated intestinal aGVHD in *Irf4*^{-/-} CD4⁺ T cell recipients. Therefore, we hypothesize that loss of *Irf4* is associated with altered functional features of donor T cells.

Irf4^{-/-} CD4⁺ T cells depict an altered Th differentiation profile on a transcriptomic level

To gain more mechanistic insight into *Irf4*-dependent T cell differentiation during GVHD, we performed transcriptome analysis of re-isolated *Irf4*^{-/-} from five recipients and *Irf4*^{+/+} donor CD4⁺ T cells from eight recipients on day 14–16 after GVHD induction (Figure 3a). Genes linked to immune cell cytokines, chemotaxis, activation proliferation and effector function were less abundant in *Irf4*^{-/-} CD4⁺ T cells compared to *Irf4*^{+/+} cells (Supplemental Figure S3A).

At protein-protein interaction level, the interactors of IRF4 (Supplemental Figure S3B) were associated with the KEGG pathways *Th differentiation*, *Cytokine-cytokine receptor interaction* and the *JAK-STAT-signaling pathway*. Mapping of the differentially

expressed genes (p-value, fold-change) onto the IRF4 STRING network predicted a downregulation of Th-differentiation associated genes except for FoxP3 and STAT-Proteins (Supplemental Figure S3B, Supplemental Table S3).

Indeed, comparing the expression levels of genes involved in Th lineage differentiation revealed an overall lower expression of genes associated to Th-1, Th-2 and Th-17 lineages and a higher expression of Th-9, Th-22, Tfh and Treg cell associated genes in the absence of *Irf4* (Figure 3b). Analysis of expression profiles of Th lineage defining transcription factors substantiated this finding (Figure 3c). In addition, genes coding for chemokine receptors, cytokines and cytokine receptors specific for Th-1, Th-2 and Th-17 were also expressed at lower levels in *Irf4*^{-/-} donor CD4⁺ T cells (Supplemental Figure S3C).

Taken together, transcriptome analysis supports the notion that IRF4 promotes pathologic effector T cell differentiation in GVHD at the expense of differentiation of T cells with protective function, such as Treg cells.




Figure 3. RNA sequencing analysis of re-isolated CD45.1⁺ CD4⁺ T cells shows differences in the transcriptomic landscape between transplanted *Irf4*^{+/+} and *Irf4*^{-/-} cells and reflects the observations described *in vivo*. Lethally irradiated BALB/c recipients received 5×10^6 CD45.2⁺ WT C57BL/6 BM depleted for CD90.2⁺ cells at day one and 1×10^6 CD4⁺ CD45.1⁺ Luciferase⁺ T cells from *Irf4*^{+/+} or *Irf4*^{-/-} donors with C57BL/6 background at day two. CD4⁺ T cells were re-isolated and sorted for CD45.1⁺ CD4⁺ T cells with high purity and RNA was extracted from these cells for RNA sequencing analysis (a). (b) T helper cell subset-regulating and -suppressing genes were plotted as mean of RNA sequencing reads between the two groups. (c) The up- and downregulation of Th-specific transcription factors between *Irf4*^{+/+} and *Irf4*^{-/-} CD4⁺ T cells was plotted by the mean of 2-fold change + standard deviation. Data represent the mean combined from two independent experiments from $n = 5$ *Irf4*^{-/-} versus $n = 8$ *Irf4*^{+/+} CD4⁺ T cell transplanted mice.

***Irf4*^{-/-} and WT CD4⁺ T cells differ in effector/memory capacity and effector function**

To test this hypothesis, we analyzed subset composition, activation, and functional marker expression on the transplanted CD45.1⁺ CD4⁺ T cells isolated from spleens of mice from *Irf4*^{-/-}, *Irf4*^{+/-} or WT groups on day 15. Whereas most WT and *Irf4*^{+/-} donor cells displayed an effector memory phenotype (T_{EM}, CD62L^{low} CD44^{high}) with a smaller contribution of effector cells (T_{eff}, CD62L⁻ CD44^{low}), *Irf4*^{-/-} donor CD4⁺ T cells had a more balanced subset composition with a majority of cells exhibiting a central memory phenotype (T_{CM}, CD62L^{high}, CD44^{high}) (Figure 4a).

In all groups, similar proportions of donor CD4⁺ T cells expressed the activation marker CD69 as well as the memory marker CD122. In contrast, surface expression of CD127 was virtually absent in *Irf4*^{-/-} donor CD4⁺ T cells, but not in WT donor cells (Figure 4b).

Analysis of effector cytokine levels by intracellular flow cytometry revealed that *Irf4*^{-/-} donor CD4⁺ T cells failed to express IFN- γ , suggesting defective Th1 polarization (Figure 4c). No substantial differences between the groups were detected for expression of the Th-17 and Th-2 specific cytokines IL-17A and IL-4, respectively (Figure 4c).

To test whether loss of *Irf4* in donor T cells expanded the Treg-cell compartment, we performed flow cytometric analyzes for the Treg-cell lineage defining transcription factor Forkhead-Box-Protein P3 (FoxP3) as well as Helios in CD45.1⁺ CD4⁺ T cells re-isolated on day 15 after irradiation. We found a higher proportion of Foxp3⁺ Treg cells within *Irf4*^{-/-} donor CD4⁺ T cells compared to controls, consistent with the transcriptome analysis (Figure 4d). Frequencies of Helios⁺ CD4⁺ T cells were elevated in *Irf4*^{-/-} donor CD4⁺ T cells to an even larger degree, suggesting that this marker is also induced in non-Treg cells (Figure 4d). In line with these findings, staining of colon tissue derived from the different groups at day 15 indicated a higher abundance of Foxp3⁺ CD3⁺ T cells in *Irf4*^{-/-} CD4⁺ T cell transplanted mice, while T-bet expression was more abundant in the WT and *Irf4*[±] group (Supplemental Figure S4).

Taken together these findings indicate that loss of *Irf4* in CD4⁺ T cells alters their differentiation trajectory, resulting in predominant differentiation into central memory cells rather than effector memory cells as well as virtually complete abrogation of Th-1 polarization and increased differentiation to Tregs which leads to differential abundance of these cell types in GVHD target tissues.

***BACH2* is strongly upregulated in *Irf4*^{-/-} CD4⁺ T cells**

One of the most upregulated differentially expressed gene (DEG) identified in the RNA sequencing analysis between *Irf4*^{-/-} and *Irf4*^{+/-} CD4⁺ T cell transplanted mice was *Bach2* (log₂fold change = 3.39; adjusted p-value = 5.59 × 10⁻⁴⁴; Figure 5a), which acts as negative regulator of *Irf4* in Tregs and Tfh cells.^{38,45} To validate differential expression of *Bach2* at protein level, we performed Western Blot analysis of *Irf4*^{-/-} and WT CD4⁺ T cells, stimulated in a mixed lymphocyte reaction (MLR). The results confirmed the absence of IRF4 and the upregulation of BACH2 in *Irf4*^{-/-} CD4⁺ T cells after

allogenic stimulation. In comparison, WT CD4⁺ T cells exhibited lower amounts on BACH2 after stimulation (Figure 5b).

We hypothesize, that IRF4 and BACH2 have opposing but tightly connected roles in the immune regulation of CD4⁺ T cells during GVHD and the development of intestinal acute GVHD.

***IRF4* but not *BACH2* expression are influenced by GVHD prophylactic therapy**

In mice, we found significantly decreased expression of *Bach2* and a trend toward higher expression of *Irf4* in colon tissue of the *Irf4*^{-/-} WT and BM control groups on transcript level. In addition, the inflammatory marker NLRP3 was also found to be upregulated in the WT group, while the *Irf4*^{-/-} group showed similar expression levels as the BMT control for all three target genes (Supplemental Figure S5).

Therefore, we wondered whether the expression of *BACH2* or *IRF4* correlated with the development of aGVHD-associated colitis following HSCT in humans. We quantified *BACH2* and *IRF4* gene transcripts in intestinal biopsies from 76 HSCT patients, during different stages of GVHD development (Supplemental Table S1). Unexpectedly, *IRF4* expression was significantly reduced during GVHD progression, whereas *BACH2* showed no major alterations (Figure 5c). We hypothesized that immunosuppressive therapy interferes with *IRF4* and *BACH2* expression. Indeed, *IRF4* expression in CD4⁺ T cells was partially abrogated upon treatment with the most common prophylactic GVHD-therapeutics, Cyclosporine A (CyA) and Methylprednisolone (MP), whereas *BACH2* expression only slightly changed (Figure 5d). These *in vitro* results reflect the observed expression patterns of *IRF4* and *BACH2* in the intestinal biopsies and might explain the lower *IRF4* expression during GVHD-associated colitis in humans, as all included patients received GVHD prophylactic CyA therapy.

To test potential consequences of elevated or reduced expression of *IRF4* and *BACH2* in biopsies, we separated patient samples in groups according to the expression of *IRF4* or *BACH2* either above or below median. Patient samples with higher *IRF4* expression exhibited elevated *NLRP3* inflammasome levels (Figure 5e). Higher FoxP3 expression was found in samples with *BACH2* expression above median (Figure 5f). These data support the idea of a relationship between *BACH2* and Treg development in human aGVHD-associated colitis.

Taken together, combined analysis of patient samples and *in vitro* experiments support the notion, that IRF4 and BACH2 contribute to shaping the immune responses in human intestinal aGVHD.

Discussion

Donor CD4⁺ T cells are the key mediators of aGVHD following HSCT. The transcription factor IRF4 plays an essential role in CD4⁺ T cell differentiation and effector function via interaction with the transcription factor BATF and Jun-factor proteins.^{46,47} As earlier studies showed, the depletion of BATF in CD4⁺ T cells abrogates aGVHD-associated colitis and the deficiency of IRF4 reduced colitis symptoms in an experimental murine colitis model.^{48,49}




Figure 4. *lrf4*^{-/-} CD4⁺ T cells exhibit an altered memory/effector and a compromised Th phenotype on comparison to *lrf4*^{+/-} and WT CD4⁺ T cells. Lethally irradiated BALB/c recipients received 5×10^6 CD45.2⁺ WT BL/6 BM cells depleted for CD90.2⁺ cells at day one and 1×10^6 CD4⁺ CD45.1⁺ Luciferase⁺ T cells from WT, *lrf4*^{-/-} or *lrf4*^{+/-} donors with BL/6 background at day two. Re-isolated CD45.1⁺ CD4⁺ T cells were analyzed for CD62L and CD44 expression to determine effector/memory development (a) and for activation- (CD69), memory- (CD122) and maturation- (CD127) markers (b) at day 15 post irradiation by flow cytometry. Representative flow cytometry plots for the distribution of *lrf4*^{+/-} (orange) and WT (red) versus *lrf4*^{-/-} (blue) CD4⁺ T cells in the effector/memory compartment are shown. (c) The differentiation to Th-1, Th-17 and Th-2 CD4⁺ T cells was determined by intracellular staining for IFN- γ , IL-17A and IL-4 respectively and flow cytometry analysis upon PMA/Ionomycin stimulation of re-isolated CD45.1⁺ CD4⁺ T cells at day 15 post irradiation. (d) Re-isolated CD45.1⁺ CD4⁺ T cells at day 15 after irradiation were analyzed for the Treg specific transcription factor FoxP3 and Helios via flow cytometry. Data represent the mean combined independent experiments from $n = 4-10$ CD4⁺ T cell transplanted mice. Data represent the mean \pm standard deviation combined from independent experiments. If applicable, all data points each representing an individual are shown. * $P < .05$, ** $P < .01$, *** $P < .0001$. Analyses were performed with the two tailed Mann-Whitney test.




Figure 5. IRF4 but not BACH2 expression are altered by GVHD immunosuppressant therapy and influence inflammatory versus anti-inflammatory signatures in intestinal biopsies of GVHD patients. (a) Lethally irradiated BALB/c recipients received 5×10^6 CD45.2⁺ WT C57BL/6 BM depleted for CD90.2⁺ cells at day one and 1×10^6 CD4⁺ CD45.1⁺ Luciferase⁺ T cells from WT, *Irf4*^{-/-} or *Irf4*^{+/-} donors with C57BL/6 background at day two. Volcano plot mapping differentially expressed genes (DEGs) between *Irf4*^{-/-} and *Irf4*^{+/-} CD4⁺ T cells described in Figure 3 satisfying the criteria of log₂ fold change > 1 or > -1 and $p < 0.05$. Significantly different expressed genes are labeled blue, genes of interest (GOI) are labeled black. (b) Western Blot detecting BACH2 and IRF4 protein expression of WT and *Irf4*^{-/-} CD4⁺ T cells before and after 10 days of MLR. WEHI-231 cells were used as control for BACH2 and IRF4 detection. β-Actin was used as loading control. (c) *IRF4* and BACH2 expression in intestinal biopsies of $n = 76$ patients who received HSCT during different stages of GVHD development analyzed by qPCR. (d) *IRF4* and BACH2 expression were quantified in CD4⁺ T cells derived from healthy donors ($n = 8$) after 3 days under stimulated or unstimulated conditions and simultaneous treatment with Cyclosporine A (CyA), Methylprednisolone (MP), a combination of both or without treatment. Samples were analyzed with Kruskal-Wallis test. Intestinal biopsies of patients ($n = 76$) who received HSCT were divided into samples expressing *IRF4* (e) or *BACH2* (f) transcripts above and below median and plotted against *NLRP3* (e) or *FoxP3* (f) expression, quantified via qPCR (e) or immunohistochemistry (f) in these samples. Samples were analyzed by two-tailed Mann-Whitney-test. Whisker-box plots indicate the mean, min and max value of individual sample sizes indicated in the respective plots. Only significant statistical test results are indicated. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$.

In this study, we identified IRF4 as an important regulator of Th-differentiation and associated inflammatory processes during GVHD in mice and human beings. The absence of *Irf4* in MHC-mismatched transplanted CD4⁺ cells abrogated GVHD development and GVHD-associated colitis in mice.

Phenotyping analysis revealed differences in the maturation and effector/memory state between transplanted *Irf4*^{-/-} and WT CD4⁺ T cells in the GVHD mouse model. Similar to what has been found in *Irf4*^{-/-} CD8⁺ T cells and for CD4⁺ T cells during acute infection,^{33,50} we observed that *Irf4*^{-/-} CD4⁺ T cells exhibited a biased differentiation to T_{CM} cells in the GVHD model. As IRF4 intrinsically translates TCR signaling strength, which

is impaired in the absence of IRF4, the model that low TCR strength enforces T cell memory potential could explain this observation.^{44,51,52} The expression of the memory markers CD127 and CD122 which were absent in *Irf4*^{-/-} CD4⁺ T cells, was also shown to be directly regulated by IRF4 in CD8⁺ T cells.⁵³ By contrast, almost all IRF4 expressing cells exhibited an effector/memory phenotype. In mice T_{EM} CD8⁺ T cells were found to be involved in GVHD-associated colitis development.⁵⁴ Hence, an altered development within the effector/memory compartment is likely to have contributed to the absence of GVHD development in *Irf4*^{-/-} CD4⁺ T cell recipients.

Functional assays and RNA sequencing of re-isolated CD4⁺ T cells indicated an impaired Th-1 differentiation and effector function in the absence of *Irf4*, which was expected since IRF4 regulates Th differentiation.⁴⁶ Wu et al. reported that *Irf4*^{-/-} CD4⁺ T cells failed to reject a heart allograft transplant.³⁵ Similar to our findings in aGVHD, *Irf4*^{-/-} CD4⁺ T cells were additionally shown to have compromised Th-1 and Th-17 differentiation capacity which led to abrogated EAE development and failure of infection control.^{33,35} Hence, Th cell dysfunctionality could have contributed to the GVHD-abrogating effect in the absence of *Irf4*. Together with FoxP3 we also detected more Helios⁺ CD4⁺ T cells when *Irf4* was absent. Helios is expressed by more activated Treg cells but is also a marker for T cell exhaustion.^{55–57} Wu et al. connected loss of *Irf4* to a higher expression of Helios and the exhaustion marker PD-1, which was reversible by anti-PD-1 antibody treatment.³⁵ Both Helios and PD-1 expression were also shown to be upregulated on activated CD4⁺ T cells when *Irf4* was suppressed by the MAK1/2 inhibitor Trametinib.³⁵ In contrast, in CD8⁺ T cells the expression of IRF4 sustained T cell exhaustion and reduction of IRF4 expression restored the functional properties of these cells.⁵⁸ Therefore, *Irf4*^{-/-} associated abrogation could be mediated by both, inhibition of Th-1 differentiation or induction of exhaustion phenotypes in T cell subsets. Additionally, we cannot exclude the lack of tissue resident T cells, which has been associated with IRF4 deficiency, as a potent mechanism for attenuated GVHD in our model.^{38,59}

Interestingly, we also found that the expression of Treg-associated transcription factors was increased in *Irf4*^{-/-} CD4⁺ T cells and a higher relative contribution of FoxP3⁺ CD4⁺ T cells was detected in murine recipients of *Irf4*^{-/-} CD4⁺ T cells. In line with that, others recently showed that more *Irf4*^{-/-} CD4⁺ T cells differentiated to FoxP3⁺ Tregs under Treg-inducing conditions.³⁸ However, one should be aware that we do not know if the increase in frequency is connected to a numerical increase of Treg cells, especially taking into account that IRF4 is necessary for tissue resident Treg maintenance and eTreg differentiation.^{36,37} In addition to FoxP3, we also found that the transcription factor BACH2, which is relevant for Treg differentiation,^{60,61} was highly expressed in *Irf4*^{-/-} CD4⁺ T cells. Interestingly, recent publications showed that IRF4 and BACH2 directly compete for the binding of transcriptional motifs in murine Tfh and Treg cells and counter regulate T cell differentiation.^{38,45} Additionally, a direct suppression of BACH2 transcription by IRF4 has been shown in B cells.⁶² Therefore, we hypothesize that the downregulation of IRF4 leads to upregulation of BACH2 which enhances the differentiation of Tregs in the GVHD model.

To validate our hypothesis, we investigated IRF4 and BACH2 expression levels in human intestinal biopsies from patients during different stages of GVHD development. Analyses were performed in a heterogeneous patient cohort at different times after HSCT and GvHD onset as well as different GvHD severity and treatment regimens and we cannot estimate how, and to which extent different immunotherapies might affect the expression of IRF4 and BACH2, thus limiting the interpretability of the data. However, we found that the immunosuppressive treatment of the patients with Cyclosporine A interfered with *IRF4* expression as reported before.⁶³ Additionally, we observed that corticosteroids

had a similar effect on *IRF4* expression, whereas *BACH2* was not affected. The impressive effect of commonly used and potent prophylaxis and first-line treatment on *IRF4* expression underscores the contribution of IRF4 to the development and progression of GVHD. However, these standard therapies are associated to unspecific immune suppression and a more targeted IRF4 inhibition might be beneficial for GVHD patients. The MEK inhibitor Trametinib, which also inhibits IRF4,³⁵ for example, has been shown to suppress GVHD while sparing GVL-effectors in mice.⁶⁴ Consistent with our observations from the mouse model, high *BACH2* levels were associated with increased expression of FoxP3 in GVHD patients. On the contrary, higher IRF4 expression levels showed a correlation with an increased NLRP3 expression, an inflammasome factor known to contribute to aGVHD induction in intestinal tissues of mice.⁶⁵

In summary, our study confirms the association of IRF4 expression with intestinal inflammatory responses as GVHD associated colitis by promoting pathologic effector T cell differentiation at the expense of differentiation of T cells with protective function, such as Treg cells. Additionally, our data support the idea that BACH2 expression is linked to Treg differentiation in mice and human. Finally, our results indicate that IRF4 and BACH2 act as counterparts in Th cell polarization and immune homeostasis during GVHD. On the aggregate strength of our data, we conclude that IRF4 could be a novel target for more targeted therapeutic approaches to treat GVHD patients in the future.

Acknowledgments

The authors thank Bushra Rais, Katja Stein, Franziska Ganß, Silvia Lindlar and Petra Schoen for their excellent technical assistance, Emilia Salzmänn- Manrique und Martin Hutter for support concerning the bioinformatics, Tobias Bopp and Virginie Lecaudey for critical discussion of the manuscript as well as Andreas Jarisch and Jan Soerensen for the provision of GVHD therapeutics.

Furthermore, we thank Andreas Beilhack from Würzburg for providing transgenic mice and discussing data. We thank Boris Brill and all animal care takers as well as Petra Dinse from the Georg Speyer Haus/FCI Frankfurt for support in mouse experiments, including colonoscopy and histological analysis.

Disclosure statement

The authors declare no conflict of interest related to this work. E.U. acts as medical advisor of Phialogics and received research funding from Gilead and Bristol-Myers Squibb. R.Z. received honorarium for participation in scientific meetings and advisory boards from Incyte, Mallinckrodt and Novartis.

Funding

This work was supported by the LOEWE Center for Cell and Gene Therapy (E.U., J.T.F.), Frankfurt, funded by the Hessian Ministry of Higher Education, Research and the Arts, Germany (III L 4- 518/17.004), by the Max-Eder Research Program of the German Cancer Aid (E.U.), by the Adolf Messer Foundation (E.U.) and the Wilhelm Sander Foundation (Grant 2017.020.002 to E.H.). J.C. was supported by the IRTG of the Collaborative Research Center CRC 1292 (TP12 to E.U.) by the Deutsche Forschungsgemeinschaft (DFG). R.Z. was supported by the DFG (SFB 850 C6, SFB1160, ZE 872/4-2, TRR167), the Deutsche Krebshilfe (grant number 70113473), and the Jose-Carreras Leukemia foundation grant number DJCLS 01 R/2019.

ORCIDEvelyn Ullrich  <http://orcid.org/0000-0001-8530-1192>**Author contributions**

J.T.F., J.C., D.Y.S.F., S.G. and S.H. performed experiments, J.T.F., J.C., D.Y.S.F., N.V., S.G., E.M., S.H. and D.H. analyzed and interpreted data. E.H., S.G. and E.M. provided human colon RNA samples, performed analyses related to human colon biopsies and helped with the interpretation and critical discussion of the results. M.L., D.S., S.S., R.S., H.B. and A.G.C. provided critical reagents and mice. D.H., E.H. and R.Z. helped to design experiments and discussed the results, A.G.C. and A.K. gave critical advice and helped with the interpretation and critical discussion of the results.

E.U. designed and directed the study; J.C., J.T.F. and E.U. wrote the manuscript with contributions of all authors.

References

- Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorrow ML, Horowitz MM, Bolwell B, Rizzo JD, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. *J Clin Oncol*. 2011;29(16):2230–2239. doi: 10.1200/JCO.2010.33.7212.
- Ayuk F, Veit R, Zabelina T, Bussmann L, Christopheit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, et al. 2015. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. *Ann Hematol*. 94(10):1727–1732. doi: 10.1007/s00277-015-2452-6.
- Carnevale-Schianca F, Leisenring W, Martin PJ, Furlong T, Schoch G, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Kiem H-P, et al. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. *Biol Blood Marrow Transplant*. 2009;15(6):749–756. doi: 10.1016/j.bbmt.2009.03.009.
- Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J, et al. 2012. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. *Blood*. 119(1):296–307. doi: 10.1182/blood-2011-06-364265.
- Inagaki J, Moritake H, Nishikawa T, Hyakuna N, Okada M, Suenobu S-I, Nagai K, Honda Y, Shimomura M, Fukano R, et al. 2015. Long-term morbidity and mortality in children with chronic graft-versus-host disease classified by National Institutes of Health Consensus criteria after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 21(11):1973–1980. doi: 10.1016/j.bbmt.2015.07.025.
- Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. *Blood*. 1990;76(8):1464–1472. doi: 10.1182/blood.V76.8.1464.1464.
- Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, Yu X-Z. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and ROR γ t in mice. *Blood*. 2011;118(18):5011–5020. doi: 10.1182/blood-2011-03-340315.
- Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, Johnston H, Young J, Todorov I, Umetsu DT, et al. 2009. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. *Blood*. 114(14):3101–3112. doi: 10.1182/blood-2009-05-219402.
- Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. *J Clin Invest*. 2000;105(9):1289–1298. doi: 10.1172/JCI7894.
- Blazar BR, Taylor PA, Panoskaltis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versus-host disease-

and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. *J Immunol*. 1998;160(11):5355–5365. doi: 10.4049/jimmunol.160.11.5355.

- Das H, Imoto S, Murayama T, Mizuno I, Sugimoto T, Taniguchi R, Toda K, Isobe T, Nakagawa T, Nishimura R, et al. 2001. Kinetic analysis of cytokine gene expression in patients with GVHD after donor lymphocyte infusion. *Bone Marrow Transplant*. 27(4):373–380. doi: 10.1038/sj.bmt.1702799.
- Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. *J Exp Med*. 2002;196(3):389–399. doi: 10.1084/jem.20020399.
- Semple K, Yu Y, Wang D, Anasetti C, Yu X-Z. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. *Biol Blood Marrow Transplant*. 2011;17(3):309–318. doi: 10.1016/j.bbmt.2010.12.710.
- Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. *Sci Transl Med*. 2011;3(83):83ra41. doi: 10.1126/scitranslmed.3001809.
- Campe J, Ullrich E. T helper cell lineage-defining transcription factors: potent targets for specific GVHD Therapy? *Front Immunol*. 2021;12:806529. doi: 10.3389/fimmu.2021.806529.
- Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. *J Immunol*. 1995;155(2):585–593. doi: 10.4049/jimmunol.155.2.585.
- Pan L, Delmonte J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. *Blood*. 1995;86(12):4422–4429. doi: 10.1182/blood.V86.12.4422.bloodjournal86124422.
- Tawara I, Maeda Y, Sun Y, Lowler KP, Liu C, Toubai T, McKenzie ANJ, Reddy P. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. *Exp Hematol*. 2008;36(8):988–996. doi: 10.1016/j.exphem.2008.02.010.
- Fulton LM, Carlson MJ, Coghill JM, Ott LE, West ML, Panoskaltis-Mortari A, Littman DR, Blazar BR, Serody JS. Attenuation of acute graft-versus-host disease in the absence of the transcription factor ROR γ t. *J Immunol*. 2012;189(4):1765–1772. doi: 10.4049/jimmunol.1200858.
- Carlson MJ, West ML, Coghill JM, Panoskaltis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. *Blood*. 2009;113(6):1365–1374. doi: 10.1182/blood-2008-06-162420.
- Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, Yu X-Z. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. *Biol Blood Marrow Transplant*. 2010;16(2):170–178. doi: 10.1016/j.bbmt.2009.09.023.
- Mittrücker HW, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. *Sci*. 1997;275(5299):540–543. doi: 10.1126/science.275.5299.540.
- Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. *J Exp Med*. 2002;195(8):1003–1012. doi: 10.1084/jem.20011128.
- Honma K, Kimura D, Tominaga N, Miyakoda M, Matsuyama T, Yui K. Interferon regulatory factor 4 differentially regulates the production of Th2 cytokines in naive vs. effector/memory CD4+ T cells. *Proc Natl Acad Sci U S A*. 2008;105(41):15890–15895. doi: 10.1073/pnas.0803171105.
- Tominaga N, Ohkusu-Tsukada K, Udono H, Abe R, Matsuyama T, Yui K. Development of Th1 and not Th2 immune responses in

- mice lacking IFN-regulatory factor-4. *Int Immunol.* 2003;15(1):1–10. doi: [10.1093/intimm/dxg001](https://doi.org/10.1093/intimm/dxg001).
26. Lohoff M, Mittrücker H-W, Prechtel S, Bischof S, Sommer F, Kock S, Ferrick DA, Duncan GS, Gessner A, Mak TW. Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. *Proc Natl Acad Sci U S A.* 2002;99(18):11808–11812. doi: [10.1073/pnas.182425099](https://doi.org/10.1073/pnas.182425099).
 27. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N, Gerlitzki B, Hoffmann M, Ulges A, Taube C, et al. 2010. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. *Immunity.* 33(2):192–202. doi: [10.1016/j.immuni.2010.07.014](https://doi.org/10.1016/j.immuni.2010.07.014).
 28. Tamiya T, Ichiyama K, Kotani H, Fukaya T, Sekiya T, Shichita T, Honma K, Yui K, Matsuyama T, Nakao T, et al. Smad2/3 and IRF4 play a cooperative role in IL-9-producing T cell induction. *J Immunol.* 2013;191(5):2360–2371. doi: [10.4049/jimmunol.1301276](https://doi.org/10.4049/jimmunol.1301276).
 29. Brüstle A, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P, Arpaia E, Mak TW, Kamradt T, Lohoff M. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. *Nat Immunol.* 2007;8(9):958–966. doi: [10.1038/ni1500](https://doi.org/10.1038/ni1500).
 30. Huber M, Brüstle A, Reinhard K, Guralnik A, Walter G, Mahiny A, von LE, Lohoff M. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. *Proc Natl Acad Sci U S A.* 2008;105(52):20846–20851. doi: [10.1073/pnas.0809077106](https://doi.org/10.1073/pnas.0809077106).
 31. Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim H-P, Oh J, Tunyaplin C, Carotta S, Donovan CE, Goldman ML, Tailor P, et al. 2009. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. *Immunity.* 31(6):941–952. doi: [10.1016/j.immuni.2009.10.008](https://doi.org/10.1016/j.immuni.2009.10.008).
 32. Bollig N, Brüstle A, Kellner K, Ackermann W, Abass E, Raifer H, Camara B, Brendel C, Giel G, Bothur E, et al. Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation. *Proc Natl Acad Sci U S A.* 2012;109(22):8664–8669. doi: [10.1073/pnas.1205834109](https://doi.org/10.1073/pnas.1205834109).
 33. Mahnke J, Schumacher V, Ahrens S, Käding N, Feldhoff LM, Huber M, Rupp J, Raczkowski F, Mittrücker H-W. Interferon regulatory factor 4 controls TH1 cell effector function and metabolism. *Sci Rep.* 2016;6:35521. doi: [10.1038/srep35521](https://doi.org/10.1038/srep35521).
 34. Yang C, He D, Yin C, Tan J. Inhibition of interferon regulatory factor 4 suppresses Th1 and Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis. *Scand J Immunol.* 2015;82(4):345–351. doi: [10.1111/sji.12334](https://doi.org/10.1111/sji.12334).
 35. Wu J, Zhang H, Shi X, Xiao X, Fan Y, Minze LJ, Wang J, Ghobrial RM, Xia J, Sciammas R, et al. Ablation of transcription factor IRF4 promotes Transplant acceptance by driving allogenic CD4+ T cell dysfunction. *Immunity.* 2017;47(6):1114–1128.e6. doi: [10.1016/j.immuni.2017.11.003](https://doi.org/10.1016/j.immuni.2017.11.003).
 36. Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S, Fagarasan S, Mielke LA, Afshar-Sterle S, Masters SL, et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. *Nat Immunol.* 2015;16(3):276–285. doi: [10.1038/ni.3085](https://doi.org/10.1038/ni.3085).
 37. Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, Belz GT, Smyth GK, Busslinger M, Nutt SL, et al. 2011. The transcription factors blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. *Nat Immunol.* 12(4):304–311. doi: [10.1038/ni.2006](https://doi.org/10.1038/ni.2006).
 38. Sidwell T, Liao Y, Garnham AL, Vasanthakumar A, Gloury R, Blume J, Teh PP, Chisanga D, Thelemann C, Rivera F de L, et al. Attenuation of TCR-induced transcription by Bach2 controls regulatory T cell differentiation and homeostasis. *Nat Commun.* 2020;11(1):252. doi: [10.1038/s41467-019-14112-2](https://doi.org/10.1038/s41467-019-14112-2).
 39. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Crawford JM, Ferrara JL. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. *Blood.* 1996;88(8):3230–3239. doi: [10.1182/blood.V88.8.3230.bloodjournal8883230](https://doi.org/10.1182/blood.V88.8.3230.bloodjournal8883230).
 40. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics.* 2014;30(15):2114–2120. doi: [10.1093/bioinformatics/btu170](https://doi.org/10.1093/bioinformatics/btu170).
 41. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):15–21. doi: [10.1093/bioinformatics/bts635](https://doi.org/10.1093/bioinformatics/bts635).
 42. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinform.* 2011;12:323. doi: [10.1186/1471-2105-12-323](https://doi.org/10.1186/1471-2105-12-323).
 43. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550. doi: [10.1186/s13059-014-0550-8](https://doi.org/10.1186/s13059-014-0550-8).
 44. Iwata A, Durai V, Tussiwand R, Briseño CG, Wu X, Grajales-Reyes GE, Egawa T, Murphy TL, Murphy KM. Quality of TCR signaling determined by differential affinities of enhancers for the composite BATF-IRF4 transcription factor complex. *Nat Immunol.* 2017;18(5):563–572. doi: [10.1038/ni.3714](https://doi.org/10.1038/ni.3714).
 45. Lahmann A, Kuhrau J, Fuhrmann F, Heinrich F, Bauer L, Durek P, Mashreghi M-F, Hutloff A. Bach2 controls T follicular helper cells by direct repression of bcl-6. *J Immunol.* 2019;202(8):2229–2239. doi: [10.4049/jimmunol.1801400](https://doi.org/10.4049/jimmunol.1801400).
 46. Huber M, Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. *Eur J Immunol.* 2014;44(7):1886–1895. doi: [10.1002/eji.201344279](https://doi.org/10.1002/eji.201344279).
 47. Li P, Spolski R, Liao W, Wang L, Murphy TL, Murphy KM, Leonard WJ. BATF-JUN is critical for IRF4-mediated transcription in T cells. *Nature.* 2012;490(7421):543–546. doi: [10.1038/nature11530](https://doi.org/10.1038/nature11530).
 48. Mudter J, Amoussina L, Schenk M, Yu J, Brüstle A, Weigmann B, Atreya R, Wirtz S, Becker C, Hoffman A, et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. *J Clin Invest.* 2008;118(7):2415–2426. doi: [10.1172/JCI33227](https://doi.org/10.1172/JCI33227).
 49. Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, et al. BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. *J Clin Invest.* 2018;128(3):916–930. doi: [10.1172/JCI89242](https://doi.org/10.1172/JCI89242).
 50. Raczkowski F, Ritter J, Heesch K, Schumacher V, Guralnik A, Höcker L, Raifer H, Klein M, Bopp T, Harb H, et al. The transcription factor Interferon regulatory factor 4 is required for the generation of protective effector CD8+ T cells. *Proc Natl Acad Sci U S A.* 2013;110(37):15019–15024. doi: [10.1073/pnas.1309378110](https://doi.org/10.1073/pnas.1309378110).
 51. Snook JP, Kim C, Williams MA. TCR signal strength controls the differentiation of CD4+ effector and memory T cells. *Sci Immunol.* 2018;3(25). doi: [10.1126/sciimmunol.aas9103](https://doi.org/10.1126/sciimmunol.aas9103).
 52. Hojyo S, Tumes D, Murata A, Tokoyoda K. Multiple developmental pathways lead to the generation of CD4 T-cell memory. *Int Immunol.* 2020;32(9):589–595. doi: [10.1093/intimm/dxaa051](https://doi.org/10.1093/intimm/dxaa051).
 53. Huang S, Shen Y, Pham D, Jiang L, Wang Z, Kaplan MH, Zhang G, Sun J. IRF4 modulates CD8+ T cell sensitivity to IL-2 family cytokines. *Immunohorizons.* 2017;1(6):92–100. doi: [10.4049/immunohorizons.1700020](https://doi.org/10.4049/immunohorizons.1700020).
 54. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. *J Immunol.* 2005;174(5):3051–3058. doi: [10.4049/jimmunol.174.5.3051](https://doi.org/10.4049/jimmunol.174.5.3051).
 55. Chennupati V, Held W. Feeling Exhausted? Tuning Irf4 Energizes Dysfunctional T Cells. *Immunity.* 2017;47(6):1009–1011. doi: [10.1016/j.immuni.2017.11.028](https://doi.org/10.1016/j.immuni.2017.11.028).
 56. Martinez RJ, Zhang N, Thomas SR, Nandiwada SL, Jenkins MK, Binstadt BA, Mueller DL. Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells. *J Immunol.* 2012;188(1):170–181. doi: [10.4049/jimmunol.1101311](https://doi.org/10.4049/jimmunol.1101311).
 57. Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, Wherry EJ. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. *Immunity.* 2014;40(2):289–302. doi: [10.1016/j.immuni.2014.01.005](https://doi.org/10.1016/j.immuni.2014.01.005).

58. Man K, Gabriel SS, Liao Y, Gloury R, Preston S, Henstridge DC, Pellegrini M, Zehn D, Berberich-Siebelt F, Febbraio MA, et al. Transcription factor IRF4 promotes CD8⁺ T cell exhaustion and limits the development of memory-like T cells during chronic infection. *Immunity*. 2017;47(6):1129–1141.e5. doi: [10.1016/j.immuni.2017.11.021](https://doi.org/10.1016/j.immuni.2017.11.021).
59. Tkachev V, Kaminski J, Potter EL, Furlan SN, Yu A, Hunt DJ, McGuckin C, Zheng H, Colonna L, Gerdemann U, et al. Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8⁺ T cells drive gastrointestinal acute graft-versus-host disease. *Sci Transl Med*. 2021;13(576). doi: [10.1126/scitranslmed.abc0227](https://doi.org/10.1126/scitranslmed.abc0227).
60. Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. *Nature*. 2013;498(7455):506–510. doi: [10.1038/nature12199](https://doi.org/10.1038/nature12199).
61. Kim EH, Gasper DJ, Lee SH, Plisch EH, Svaren J, Suresh M. Bach2 regulates homeostasis of Foxp3⁺ regulatory T cells and protects against fatal lung disease in mice. *J Immunol*. 2014;192(3):985–995. doi: [10.4049/jimmunol.1302378](https://doi.org/10.4049/jimmunol.1302378).
62. Hu Q, Xu T, Zhang M, Zhang H, Liu Y, Li H-B, Chen C, Zheng J, Zhang Z, Li F, et al. Diverging regulation of Bach2 protein and RNA expression determine cell fate in early B cell response. *Cell Rep*. 2022;40(1):111035. doi: [10.1016/j.celrep.2022.111035](https://doi.org/10.1016/j.celrep.2022.111035).
63. Matsuyama T, Grossman A, Mittrücker HW, Siderovski DP, Kiefer F, Kawakami T, Richardson CD, Taniguchi T, Yoshinaga SK, Mak TW. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). *Nucleic Acids Res*. 1995;23(12):2127–2136. doi: [10.1093/nar/23.12.2127](https://doi.org/10.1093/nar/23.12.2127).
64. Itamura H, Shindo T, Tawara I, Kubota Y, Kariya R, Okada S, Komanduri KV, Kimura S. The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects. *JCI Insight*. 2016;1(10):e86331. doi: [10.1172/jci.insight.86331](https://doi.org/10.1172/jci.insight.86331).
65. Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber FC, Guarda G, Follo M, Pfeifer D, Tardivel A, Ludigs K, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. *J Exp Med*. 2013;210(10):1899–1910. doi: [10.1084/jem.20130084](https://doi.org/10.1084/jem.20130084).